Brief: Bellicum Announces Interim Results Showing Low Rates Of Cancer Recurrence In Pediatric AML Patients Treated With BPX-501

Bellicum Pharmaceuticals

13/03/2018 11:13

March 13 (Reuters) - Bellicum Pharmaceuticals Inc  BLCM.O :
    * BELLICUM ANNOUNCES INTERIM RESULTS SHOWING LOW RATES OF
CANCER
RECURRENCE IN PEDIATRIC AML PATIENTS TREATED WITH BPX-501
    * BELLICUM PHARMA - WORKING WITH INVESTIGATORS & U.S. FDA TO
DEVELOP PROTOCOL FOR POTENTIAL U.S. REGISTRATION STUDY IN
PEDIATRIC PATIENTS
    * BELLICUM PHARMA - EXPECTS TO INITIATE POTENTIAL U.S.
REGISTRATION STUDY IN PEDIATRIC PATIENTS BY END OF 2018
    * BELLICUM PHARMA - FROM BP-004 STUDY, CO REPORTED HIGH
RATES OF
DISEASE-FREE SURVIVAL & OVERALL SURVIVAL IN PEDIATRIC PATIENTS
WITH PID

Source text for Eikon:  ID:nGNX7qT7fJ 
Further company coverage:  BLCM.O 

 ((Reuters.Briefs@thomsonreuters.com;))